Stockreport

Werewolf Therapeutics Announces Pipeline and Business Updates

Werewolf Therapeutics, Inc.  (HOWL) 
PDF WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma p [Read more]